120577-33-5

Basic information

• Product Name: (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine
• Synonyms: (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine
• CAS NO: 120577-33-5
• Molecular Formula: C₁₅H₂₂N₂
• Molecular Weight: 230.34858
• Mol File: 120577-33-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 332.137°C at 760 mmHg
• Flash Point: 127.544°C
• Appearance: /
• Density: 1.065g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.578
• PKA: 10.50±0.33(Predicted)
• CAS DataBase Reference: (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine(120577-33-5)
• EPA Substance Registry System: (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine(120577-33-5)

Safety Data

• Hazardous Substances Data: 120577-33-5(Hazardous Substances Data)

Usage

General Description

(R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine is a chemical compound that belongs to the class of quinuclidine derivatives. It is a chiral compound with a stereocenter at the nitrogen atom, which means it has two enantiomeric forms, (R) and (S). (R)-N-((S)-1-phenylethyl)quinuclidin-3-aMine has potential biological activity and has been studied for its pharmacological properties, particularly its potential as a cholinergic agonist. It may have applications in the development of drugs for conditions such as Alzheimer's disease and Parkinson's disease. Additionally, it may also have applications in the field of organic synthesis and medicinal chemistry.

InChI:InChI=1/C15H22N2/c1-12(13-5-3-2-4-6-13)16-15-11-17-9-7-14(15)8-10-17/h2-6,12,14-16H,7-11H2,1H3/t12-,15-/m0/s1

Upstream product

• 120570-06-1 N-((S)-1-phenylethyl)-3-quinuclidinimine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 3731-38-2 3-Quinuclidinone 

Downstream Products

• 6530-09-2 (3R)-quinuclidin-3-amine dihydrochloride 

Relevant articles and documents

Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl]benzamide and its 5-halogen-2-alkoxyl homologues

(S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [125I]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [125I]-MIZAC at 1800 Ci/mmol. Binding of [125I]-MIZAC in rat entorhinal cortex revealed a K(D) of 1.37 ± 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [125I]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [125I]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.

Heterocyclic compounds useful as 5-HT3 antagonists

Aroyl ureas and carbamic acid derivatives of formula and pharmaceutically acceptable salts thereof wherein A is a specified aromatic radical including optionally substituted phenyl W is O or S Y is NH or S and B is a specified saturated azacyclic ring, eg tropan-3-yl or quinuclidin-3-yl, possess 5-HT3 -antagonistic activity and are, for example, useful in treatment of migraine, emesis, anxiety, gastro-intestinal disorders and as anti-psychotics.